Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31461
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVermersch, P.-
dc.contributor.authorEralinna, J.-
dc.contributor.authorNicholas, R.-
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorSiva, A.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorWiendl, H.-
dc.contributor.authorBuffels, R.-
dc.contributor.authorWei, W.-
dc.contributor.authorComi, G.-
dc.date.accessioned2020-07-10T12:22:29Z-
dc.date.available2020-07-10T12:22:29Z-
dc.date.issued2020-
dc.date.submitted2020-07-08T10:47:46Z-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 26 (1_SUPPL) , p. 32 -32-
dc.identifier.urihttp://hdl.handle.net/1942/31461-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.rights2020 by SAGE Publications.-
dc.titleEfficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateFEB 27-29, 2020-
local.bibliographicCitation.conferencenameAmericas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-
local.bibliographicCitation.conferencename(ACTRIMS) Forum-
local.bibliographicCitation.conferenceplaceWest Palm Beach, FL-
dc.identifier.epage32-
dc.identifier.issue1_SUPPL-
dc.identifier.spage32-
dc.identifier.volume26-
local.format.pages1-
local.bibliographicCitation.jcatM-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isiWOS:000532412600068-
dc.identifier.eissn1477-0970-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Vermersch, P.] Univ Lille, Lille, France.-
local.description.affiliation[Eralinna, J.] NEO Res, Turku, Finland.-
local.description.affiliation[Nicholas, R.] Imperial Coll Healthcare NHS Trust, London, England.-
local.description.affiliation[Nicholas, R.] Imperial Coll, London, England.-
local.description.affiliation[Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain.-
local.description.affiliation[Siva, A.] Istanbul Univ, Cerrahpasa Fac Med, Cerrahpasa, Turkey.-
local.description.affiliation[Van Wijmeersch, B.] Univ Hasselt, Overpelt, Belgium.-
local.description.affiliation[Van Wijmeersch, B.] Rehabil & MS Ctr, Overpelt, Belgium.-
local.description.affiliation[Wiendl, H.] Univ Munster, Munster, Germany.-
local.description.affiliation[Buffels, R.; Wei, W.] F Hoffmann Roche Ltd, Basel, Switzerland.-
local.description.affiliation[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
item.fulltextWith Fulltext-
item.contributorVermersch, P.-
item.contributorEralinna, J.-
item.contributorNicholas, R.-
item.contributorOreja-Guevara, C.-
item.contributorSiva, A.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorWiendl, H.-
item.contributorBuffels, R.-
item.contributorWei, W.-
item.contributorComi, G.-
item.fullcitationVermersch, P.; Eralinna, J.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Wei, W. & Comi, G. (2020) Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results). In: MULTIPLE SCLEROSIS JOURNAL, 26 (1_SUPPL) , p. 32 -32.-
item.accessRightsRestricted Access-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
vermersch_2020.pdf
  Restricted Access		Published version107.04 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.